Hematology · Dermatology ·
International recommendations address advanced mycosis fungoides and Sézary syndrome
An international multidisciplinary panel of 30 experts developed consensus recommendations for systemic treatment and allogeneic hematopoietic cell transplantation in advanced mycosis fungoides and Sézary syndrome. The guidance proposes stage-adapted, compartment-oriented treatment and outlines sequencing across systemic and skin-directed therapies.
- Thirty experts developed multidisciplinary consensus recommendations.
- Treatment approach is stage- and disease-compartment-oriented.
- Several systemic therapies and combinations are discussed.
- Allogeneic transplantation is presented as potentially curative for selected patients.
An international panel of 30 experts convened by the European Hematology Association, the EORTC Cutaneous Lymphoma Tumours Group, the International Society for Cutaneous Lymphoma, and the EBMT Lymphoma Working Party reviewed available evidence and developed recommendations for advanced mycosis fungoides (MF) and Sézary syndrome (SS). The guidance covers diagnostic work-up, systemic treatment, sequencing and combinations, and indications for allogeneic hematopoietic cell transplantation (allo-HCT). The source abstract does not report a formal evidence-grading method or patient-level study data.
The recommendations favor a stage-adapted, compartment-oriented approach. Extracorporeal photopheresis is commonly used first line in SS and in patients with substantial blood involvement; interferon-α and retinoids are widely used in MF, often alongside skin-directed therapies. Mogamulizumab and brentuximab vedotin are described as options after prior systemic treatment, with differing activity across skin, blood, and nodal disease. The panel also proposes combination approaches and practical treatment algorithms. Allo-HCT is characterized as the only potentially curative treatment and should be considered early for selected patients with high-risk disease features. These are consensus recommendations based on reviewed evidence; the supplied abstract does not provide detailed evidence ratings or the full algorithms.
In practice
For patients with advanced MF or SS, the recommendations support tailoring treatment to disease stage and the involved compartment. They describe extracorporeal photopheresis as commonly used first line in SS or substantial blood involvement, and interferon-α or retinoids as widely used in MF, often with skin-directed therapy. Mogamulizumab and brentuximab vedotin are options after prior systemic treatment; allo-HCT may be considered early in selected high-risk patients. These are consensus recommendations, and the supplied abstract provides no evidence grades or detailed algorithms; it does not establish that practice should change for every patient.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
HemaSphere: Management of advanced mycosis fungoides and Sézary Syndrome: International Recommendations for systemic treatments and allogeneic hematopoietic cell transplantation from the European Hematology Association, the EORTC Cutaneous Lymphoma Tumours Group, the International Society for Cutaneous Lymphoma, and the Lymphoma Working Party of the EBMT ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.